Sue Fischer Email

SVP Development Operations . Aerovate Therapeutics

Current Roles

Employees:
50
Revenue:
$5.6M
About
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's lead program is a potentially disease modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH).
Aerovate Therapeutics Address
Boston, MA 02116, US
Boston, MA
United States
Aerovate Therapeutics Email

Past Companies

Aerovate Therapeutics, Inc.Senior Vice President Development Operations
Syndax PharmaceuticalsVice President-Clinical Operations
Acetylon Pharmaceuticals, Inc.Associate Vice President-Clinical Operations

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.